<DOC>
	<DOC>NCT00793273</DOC>
	<brief_summary>This study is conducted in Europe. The aim of this observational study is to observe the efficacy of Levemir速 treatment in patients with type 2 diabetes in everyday clinical practice in Switzerland. Furthermore the time period between diagnosis of type 2 diabetes and insulin initiation is evaluated.</brief_summary>
	<brief_title>Observational Study to Observe the Efficacy of Levemir速 (Insulin Detemir) in Patients With Type 2 Diabetes.</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<criteria>Patients with type 2 diabetes mellitus Insulinnaive or currently treated with another basal insulin Inclusion of patients at the discretion of the treating physician after the decision to prescribe Levemir速 Type 1 diabetes mellitus Patients treated with short acting or with premix insulin Women who are pregnant, breast feeding or have the intention to become pregnant Known or suspected allergy to the study product or related product Any exclusion criteria according to the Swiss Levemir速 SPC (Summary of Product Characteristics)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>